trending Market Intelligence /marketintelligence/en/news-insights/trending/rvYXLlXaiFRKJNzKWF-3eA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Genor Biopharma to raise $200M from Hong Kong IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Genor Biopharma to raise $200M from Hong Kong IPO

Genor BioPharma Co. Ltd. is planning to raise about $200 million from a Hong Kong IPO, Bloomberg News reported, citing people familiar with the matter.

Shanghai-based Genor BioPharma, which develops treatments for cancer, autoimmune and metabolic diseases, got in touch with potential advisers for the share sale, anonymous sources told the news outlet.

The listing of Genor BioPharma's shares under the IPO could occur in mid-2020, according to the report.

The pharmaceutical company, which is supported by private equity firm Hillhouse Capital Management Ltd., has raised about $100 million from private investors this year, Bloomberg News noted in an October article.

Genor BioPharma's valuation could reach $1 billion following the IPO, Bloomberg said, citing people familiar with the matter.